Naloxonazine | 82824-01-9

• 分子结构分类: 有机化合物 - 苯类化合物 - 菲及其衍生物
• 英文名称: Naloxonazine
• 英文别名: (4R,4aS,7E,7aR,12bS)-7-[(E)-[(4R,4aS,7aR,12bS)-4a,9-dihydroxy-3-prop-2-enyl-2,4,5,6,7a,13-hexahydro-1H-4,12-methanobenzofuro[3,2-e]isoquinolin-7-ylidene]hydrazinylidene]-3-prop-2-enyl-2,4,5,6,7a,13-hexahydro-1H-4,12-methanobenzofuro[3,2-e]isoquinoline-4a,9-diol
• CAS: 82824-01-9
• 化学式: C₃₈H₄₂N₄O₆
• 分子量: 650.8
• InChiKey: AJPSBXJNFJCCBI-YOHUGVJRSA-N

物化性质

• 密度：
  1.58±0.1 g/cm3(Predicted)
• 溶解度：
  H2O:>2 mg/mL

计算性质

• 辛醇/水分配系数(LogP)：
  4
• 重原子数：
  48
• 可旋转键数：
  5
• 环数：
  10.0
• sp3杂化的碳原子比例：
  0.53
• 拓扑面积：
  131
• 氢给体数：
  4
• 氢受体数：
  10

安全信息

• WGK Germany：
  3

文献信息

• [EN] TARGETED DRUG DELIVERY THROUGH AFFINITY BASED LINKERS<br/>[FR] ADMINISTRATION CIBLÉE D'UN MÉDICAMENT FAISANT APPEL À DES COUPLEURS FONDÉS SUR L'AFFINITÉ
  申请人：INVICTUS ONCOLOGY PVT LTD

  公开号：WO2015148126A1

  公开（公告）日：2015-10-01

  The current invention discloses targeted drug delivery conjugates comprising a targeting moiety linked to a drug via a molecule having an affinity for the targeting moiety. Typically, the conjugate comprises a targeting ligand and a molecule of interest, e.g., a therapeutic agent. The targeting ligand and the molecule of interest are linked to each other via an affinity ligand. The affinity ligand is further covalently or non-covalently linked to a drug or therapeutic agent. The drug can be modified to make it more soluble and so that it cleaves from the linking molecule at the target site.

  当前的发明揭示了包括通过具有与靶向基团亲和力的分子连接到药物的靶向药物传递共轭物。通常，该共轭物包括一个靶向配体和一个感兴趣的分子，例如，一个治疗剂。靶向配体和感兴趣的分子通过一个亲和配体相互连接。该亲和配体进一步以共价或非共价方式连接到药物或治疗剂。药物可以被修改以使其更溶解，并使其在靶点处从连接分子中解离。
• PERHYDROQUINOXALINE DERIVATIVES
  申请人：Wünsch Bernhard

  公开号：US20100311761A1

  公开（公告）日：2010-12-09

  The present invention relates to perhydroquinoxaline derivatives, processes for their preparation, their use for the preparation of a medicament and medicaments containing perhydroquinoxaline derivatives.

  本发明涉及过氢喹喔啉衍生物，其制备方法，其用于制备药物以及含有过氢喹喔啉衍生物的药物。
• THIAZOLIDINONE COMPOUNDS AND USE THEREOF
  申请人：National Health Research Institutes

  公开号：US20170253569A1

  公开（公告）日：2017-09-07

  A pharmaceutical composition containing a compound of Formula (I) for treating an opioid receptor-associated condition. Also disclosed is a method for treating an opioid receptor-associated condition using such a compound. Further disclosed are two sets of thiazolidinone compounds of formula (I): (i) compounds each having an enantiomeric excess greater than 90% and (ii) compounds each being substituted with deuterium.

  一种含有化合物（I）的药物组合物，用于治疗与阿片受体相关的疾病。还公开了一种使用这种化合物治疗阿片受体相关疾病的方法。进一步公开了两组式（I）的噻唑烷酮化合物：（i）每种化合物的对映体过量大于90%；（ii）每种化合物被氘取代。
• [EN] POLYPEPTIDE-OPIOID CONJUGATES AND USES THEREOF<br/>[FR] CONJUGUÉS POLYPEPTIDES OPIOÏDES ET UTILISATIONS ASSOCIÉES
  申请人：ANGIOCHEM INC

  公开号：WO2013056096A1

  公开（公告）日：2013-04-18

  The invention features polypeptide-opioid conjugates capable of crossing the blood-brain barrier. The polypeptide-opioid conjugates can be used to treat a condition that is modulated by opioid receptors such as pain (e.g., postoperative pain, cancer pain, acute pain, and chronic pain).

  这项发明涉及能够穿越血脑屏障的多肽-阿片类肽共轭物。这些多肽-阿片类肽共轭物可用于治疗受阿片类受体调节的疾病，如疼痛（例如术后疼痛、癌症疼痛、急性疼痛和慢性疼痛）。
• [EN] PERHYDROQUINOXALINE DERIVATIVES USEFUL AS ANALGESICS<br/>[FR] DÉRIVÉS DE PÉRHYDROQUINOXALINE UTILES EN TANT QU'ANALGÉSIQUES
  申请人：WOLFF AUGUST GMBH & CO KG ARZNEIMITTEL DR

  公开号：WO2014184355A1

  公开（公告）日：2014-11-20

  The present invention relates to perhydroquinoxaline compounds according to the general formula (1), their use as a medicament, in particular as analgesic, antipruritic and antiinflammatory agents, and their preparation.

  本发明涉及按照通式（1）的过氧化喹啉化合物，其作为药物的用途，特别是作为镇痛、止痒和抗炎药剂，以及它们的制备。